Artículo Original Referencias 1.- Lambert R, Guilloux A, Oshima A, 16 Pompe-Kirn V, Bray F, Parkin M, et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 2002; 97: 811-8. 2.- Csendes A, Smok G, Medina E, et al. Clinical course characteristics of gastric cancer 1958-1990. Rev Med Chile 1992; 120: 36-42. 3.- Calvo A, Pruyas M, Nilsen E, Verdugo P. Frequency of gastric cancer in endoscopies performed in symptomatic patients at a Secondary Care Health Center. Rev Med Chile 2001; 129: 749-55. 4.- Heise K, Bertran E, Andia ME, Ferreccio C. Incidence and survival of stomach cancer in a high-risk population of Chile. World J Gastroenterol 2009; 15: 1854-62. 5.- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin 2011; 61: 69. 6.- Tapia O, Roa J, Manterola C, Villaseca M, Gutiérrez V, Flores P, et al. Cáncer gástrico en una región de Chile: Comparación de variables clínicas y morfológicas en dos períodos (1986-1995 y 1996-2005). Rev Chil Cir 2010; 62: 125-30. 7.- Muller B, De la Fuente H, Baraja O, Cardemil B, Vila A, Mordojovich E, et al. Registro de evaluación de tratamiento de cáncer gástrico en Chile (REGATE): Características clínicas basales de 523 pacientes. Rev Chil Cir 2011; 63: 147-53. 8.- Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002; 5: 1-5. 9.- Recommendations for clinical practice: 2004 Standards, Options and Recommendations for management of patients with adenocarcinomas of the stomach (excluding cardial and other histological forms of cancer) Federation nationale des centres de lutte contre le cancer. Gastroenterol Clin Biol 2005; 29: 41-55. 10.- McColl KE. Screening for early gastric cancer. Gut 2005; 54: 740-2. 11.- Tashiro A, Sano M, Kinameri K, Fujita K, Takeuchi Y. Comparing mass screening techniques for gastric cancer in Confia bilidad de limpie za en endoscopia digestiva alta - R. Mansilla V. et al. Japan. World J Gastroenterol 2006; 12: 4873-4. 12.- Everett SM, Axon AT. Early gastric cancer: disease or pseudo-disease? Lancet 1998; 351: 1350-2. 13.- Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001; 48: 225-9. 14.- Chávez Rossell M. Endoscopic treatment of early gastric cancer: from Endoscopic Mucosal Resection (EMR) to Endoscopic Submucosal Dissection (ESD). Rev Gastroenterol Peru 2005; 25: 76-92. 15.- Rollán A, Cortés P, Calvo A, Araya R, Bufadel M, González R, et al. Diagnóstico precoz de cáncer gástrico. Propuesta de detección y seguimiento de lesiones premalignas gástricas: protocolo ACHED. Rev Med Chile 2014; 142: 1181-92. 16.- Cohen J, Safdi MA, Deal SE, Baron TH, Chak A, Hoffman B, et al. Quality indicators for esophagogastroduodenoscopy. Am J Gastroenterol 2006; 101; 886-91. 17.- Gómez M, Ricaurte O, Gutiérrez O. Costo efectividad de la endoscopia digestiva alta como prueba diagnóstica en una campaña para detección del cáncer gástrico. Rev Colomb Gastroent 2009; 24: 34-50. 18.- Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81. 19.- Kwan V, Devíere J. Endoscopy essentials: preparation, sedation, and surveillance: Endoscopy 2008; 40: 65-70. 20.- Banerjee B, Parker J, Waits W, Davis B. Effectiveness of preprocedure simethicone drink in improving visibility during esophagogastroduodenoscopy: a double-blind, randomized study. J Clin Gastroenterol 1992; 15: 264-5. 21.- Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O’Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44: 74-94. 22.- Bhandari P, Green S, Hamanaka H, Nakajima T, Matsuda T, Saito Y, et al. Use of Gascon and Pronase either as a pre-endoscopic drink or as targeted endoscopic flushes to improve visibility during gastroscopy: a prospective, randomized, controlled, blinded trial. Scand J Gastroenterol 2010; 45: 357-61. 23.- Información sobre simeticona. Disponible en: http://www.uptodate.com/contents/ search?search=simeticona Uptodate, Consultado el 1 de diciembre de 2015. 24.- McDonald GB, O’Leary R, Stratton C. Pre-endoscopic use of oral simethicone. Gastrointest Endosc 1978; 24: 283. 25.- Banerjee B, Parker J, Waits W, Davis B. Effectiveness of preprocedure simethicone drink in improving visibility during esophagogastroduodenoscopy: a double-blind, randomized study. J Clin Gastroenterol 1992; 15: 264-5. 26.- McNally PR, Maydonovitch CL, Wong RK. The effectiveness of simethicone in improving visibility during colonoscopy: a double-blind randomized study. Gastrointest Endosc 1988; 34: 255-8. 27.- Tongprasert S, Sobhonslidsuk A, Rattanasiri S. Improving quality of colonoscopy by adding simethicone to sodium phosphate bowel preparation. World J Gastroenterol 2009; 15: 3032-7. 28.- Albert J, Gobel CM, Lesske J, Lotterer E, Nietsch H, Fleig WE. Simethicone for small bowel preparation for capsule endoscopy: a systematic, single-blinded, controlled study. Gastrointest Endosc 2004; 59: 487-91. 29.- Fang YH, Chen CX, Zhang BL. Effect of small bowel preparation with simethicone on capsule endoscopy. J Zhejiang Univ Sci B 2009; 10: 46-51. 30.- Chang CC, Chen SH, Lin CP, Hsieh CR, Lou HY, Suk FM, et al. Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, Gastroenterol. latinoam 2016; Vol 27, Nº 1: 9-17
gastro-1-2016
To see the actual publication please follow the link above